Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Ischemic Heart Disease

Free Subscription Articles published in Lancet Retrieve available abstracts of 140 articles: HTML format Text format

Single Articles

October 2019
1. VON BIRGELEN C, Buiten RA
   Superiority of biodegradable polymer sirolimus-eluting stents in STEMI.
   Lancet. 2019;394:1208-1210.
   PubMed     Text format    
   
   
   September 2019
2. HAUSENLOY DJ, Kharbanda RK, Moller UK, Ramlall M, et al
   Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
   Lancet. 2019 Sep 6. pii: S0140-6736(19)32039.
   PubMed     Text format     Abstract available
   
   
   
3. READ SH, Wild SH
   Prevention of premature cardiovascular death worldwide.
   Lancet. 2019 Sep 2. pii: S0140-6736(19)32034.
   PubMed     Text format    
   
   
   
4. VRANCKX P, Valgimigli M, Eckardt L, Tijssen J, et al
   Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
   Lancet. 2019 Sep 2. pii: S0140-6736(19)31872.
   PubMed     Text format     Abstract available
   
   
   
5. YUSUF S, Joseph P, Rangarajan S, Islam S, et al
   Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
   Lancet. 2019 Sep 2. pii: S0140-6736(19)32008.
   PubMed     Text format     Abstract available
   
   
   August 2019
6. IGLESIAS JF, Muller O, Heg D, Roffi M, et al
   Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
   Lancet. 2019 Aug 30. pii: S0140-6736(19)31877.
   PubMed     Text format     Abstract available
   
   
   
7. THUIJS DJFM, Kappetein AP, Serruys PW, Mohr FW, et al
   Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.
   Lancet. 2019 Aug 30. pii: S0140-6736(19)31997.
   PubMed     Text format     Abstract available
   
   
   
8. TAGGART DP, Pagano D
   Expansion or contraction of stenting in coronary artery disease?
   Lancet. 2019 Aug 30. pii: S0140-6736(19)32040.
   PubMed     Text format    
   
   
   
9. SCHWALM JD, McCready T, Lopez-Jaramillo P, Yusoff K, et al
   A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial.
   Lancet. 2019 Aug 30. pii: S0140-6736(19)31949.
   PubMed     Text format     Abstract available
   
   
   
10. JAFAR TH, Samad Z, Bloomfield GS
    Parallel community solutions for cardiovascular risk reduction.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31995.
    PubMed     Text format    
    
    
    
11. BHATT DL, Steg PG, Mehta SR, Leiter LA, et al
    Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31887.
    PubMed     Text format     Abstract available
    
    
    
12. STAFF AC
    Long-term cardiovascular health after stopping pre-eclampsia.
    Lancet. 2019 Aug 28. pii: S0140-6736(19)31993.
    PubMed     Text format    
    
    
    
13. NASLUND U, Ng N, Wennberg P, Norberg M, et al
    Patient-doctor engagement in cardiovascular prevention - Authors' reply.
    Lancet. 2019;394:e27.
    PubMed     Text format    
    
    
    
14. ANYFANTI P, Gkaliagkousi E, Douma S
    Patient-doctor engagement in cardiovascular prevention.
    Lancet. 2019;394:e26.
    PubMed     Text format    
    
    
    
15. RAY KK, Corral P, Morales E, Nicholls SJ, et al
    Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options.
    Lancet. 2019;394:697-708.
    PubMed     Text format     Abstract available
    
    
    
16. GUPTA R, Wood DA
    Primary prevention of ischaemic heart disease: populations, individuals, and health professionals.
    Lancet. 2019;394:685-696.
    PubMed     Text format     Abstract available
    
    
    
17. ROSHANDEL G, Khoshnia M, Poustchi H, Hemming K, et al
    Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet. 2019;394:672-683.
    PubMed     Text format     Abstract available
    
    
    
18. STRONGMAN H, Gadd S, Matthews A, Mansfield KE, et al
    Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases.
    Lancet. 2019 Aug 20. pii: S0140-6736(19)31674.
    PubMed     Text format     Abstract available
    
    
    
19. BLAES AH, Shenoy C
    Is it time to include cancer in cardiovascular risk prediction tools?
    Lancet. 2019 Aug 20. pii: S0140-6736(19)31886.
    PubMed     Text format    
    
    
    
20. NASLUND U, Lundgren A, Vanoli D, Norberg M, et al
    Is intima-media thickness a predictor for cardiovascular risk? - Authors' reply.
    Lancet. 2019;394:381.
    PubMed     Text format    
    
    
    
21. GONZALEZ-CANTERO A, Gonzalez-Cantero J, Sanchez-Moya AI, Rodriguez-Padial L, et al
    Is intima-media thickness a predictor for cardiovascular risk?
    Lancet. 2019;394:380-381.
    PubMed     Text format    
    
    
    July 2019
22. HERRETT E, Gadd S, Jackson R, Bhaskaran K, et al
    Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study.
    Lancet. 2019 Jul 25. pii: S0140-6736(19)31359.
    PubMed     Text format     Abstract available
    
    
    June 2019
23. BARNETT R
    Acute myocardial infarction.
    Lancet. 2019;393:2580.
    PubMed     Text format    
    
    
    
24. TIJSSEN RYG, de Winter RJ, Wykrzykowska JJ
    ABSORB IV: will the low rate of scaffold thrombosis persist?
    Lancet. 2019;393:2392.
    PubMed     Text format    
    
    
    
25. STONE GW, Ellis SG, Kereiakes DJ
    ABSORB IV: will the low rate of scaffold thrombosis persist? - Authors' reply.
    Lancet. 2019;393:2392-2393.
    PubMed     Text format    
    
    
    
26. RISSANEN TT, Uskela S, Eranen J, Mantyla P, et al
    Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial.
    Lancet. 2019 Jun 13. pii: S0140-6736(19)31126.
    PubMed     Text format     Abstract available
    
    
    
27. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31149.
    PubMed     Text format     Abstract available
    
    
    
28. OIKONOMOU EK, Antoniades C
    Detection of coronary inflammation - Authors' reply.
    Lancet. 2019;393:2199-2200.
    PubMed     Text format    
    
    
    May 2019
29. RABER I, McCarthy CP, Vaduganathan M, Bhatt DL, et al
    The rise and fall of aspirin in the primary prevention of cardiovascular disease.
    Lancet. 2019;393:2155-2167.
    PubMed     Text format     Abstract available
    
    
    
30. FUDIM M, Ali-Ahmed F, Patel MR, Sobotka PA, et al
    Sham trials: benefits and risks for cardiovascular research and patients.
    Lancet. 2019;393:2104-2106.
    PubMed     Text format    
    
    
    
31. JEGER RV, Kaiser C, Gilgen N, Coslovsky M, et al
    Drug-coated balloons: room for development of BASKET-SMALL 2 - Authors' reply.
    Lancet. 2019;393:1934-1935.
    PubMed     Text format    
    
    
    
32. SAJADIEH A, Kumarathurai P, Jeppesen JL
    Drug-coated balloons: room for development of BASKET-SMALL 2.
    Lancet. 2019;393:1934.
    PubMed     Text format    
    
    
    
33. ALFONSO F, Guimaraes MG, Rivero F, Cuesta J, et al
    Drug-coated balloons: room for development of BASKET-SMALL 2.
    Lancet. 2019;393:1933-1934.
    PubMed     Text format    
    
    
    
34. SHAH R, Khan B
    The MATRIX trial.
    Lancet. 2019;393:1803.
    PubMed     Text format    
    
    
    
35. MEYER TM, Hollenbeck M, Kielstein JT
    The MATRIX trial.
    Lancet. 2019;393:1802-1803.
    PubMed     Text format    
    
    
    
36. PICCOLO R, Bonaa KH, Efthimiou O, Varenne O, et al
    Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials.
    Lancet. 2019 May 2. pii: S0140-6736(19)30474.
    PubMed     Text format     Abstract available
    
    
    
37. JENSEN LO, Christiansen EH
    Are drug-eluting stents safer than bare-metal stents?
    Lancet. 2019 May 2. pii: S0140-6736(19)31000.
    PubMed     Text format    
    
    
    April 2019
38. MCCALL B
    Alemtuzumab to be restricted pending review, says EMA.
    Lancet. 2019;393:1683.
    PubMed     Text format    
    
    
    
39. MILLWOOD IY, Walters RG, Mei XW, Guo Y, et al
    Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China.
    Lancet. 2019 Apr 4. pii: S0140-6736(18)31772.
    PubMed     Text format     Abstract available
    
    
    March 2019
40. THE LANCET EDITORS
    Retraction-Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.
    Lancet. 2019;393:1084.
    PubMed     Text format    
    
    
    
41. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.
    PubMed     Text format    
    
    
    
42. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.
    PubMed     Text format    
    
    
    
43. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    PubMed     Text format    
    
    
    
44. BAX JJ, Di Carli M, Narula J, Delgado V, et al
    Multimodality imaging in ischaemic heart failure.
    Lancet. 2019;393:1056-1070.
    PubMed     Text format     Abstract available
    
    
    
45. MCCRINDLE BW, Rowley AH
    Improving coronary artery outcomes for children with Kawasaki disease.
    Lancet. 2019 Mar 7. pii: S0140-6736(18)33133.
    PubMed     Text format    
    
    
    
46. HAMADA H, Suzuki H, Onouchi Y, Ebata R, et al
    Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised
    Lancet. 2019 Mar 7. pii: S0140-6736(18)32003.
    PubMed     Text format     Abstract available
    
    
    February 2019
47. KIMURA T
    Can ultra-thin strut drug-eluting stents improve outcomes?
    Lancet. 2019 Feb 28. pii: S0140-6736(19)30286.
    PubMed     Text format    
    
    
    
48. ZAMAN A, de Winter RJ, Kogame N, Chang CC, et al
    Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.
    Lancet. 2019 Feb 28. pii: S0140-6736(18)32467.
    PubMed     Text format     Abstract available
    
    
    
49. MEHRAN R, Vogel B, Ortega R, Cooney R, et al
    The Lancet Commission on women and cardiovascular disease: time for a shift in women's health.
    Lancet. 2019 Feb 8. pii: S0140-6736(19)30315.
    PubMed     Text format    
    
    
    December 2018
50. NASLUND U, Ng N, Lundgren A, Fharm E, et al
    Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial.
    Lancet. 2018 Dec 3. pii: S0140-6736(18)32818.
    PubMed     Text format     Abstract available
    
    
    November 2018
51. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Lancet. 2018 Nov 9. pii: S0140-6736(18)32590.
    PubMed     Text format     Abstract available
    
    
    October 2018
52. COLOMBO A, Giannini F
    Encouraging data from ABSORB IV pave the way to new scaffolds.
    Lancet. 2018;392:1490-1491.
    PubMed     Text format    
    
    
    
53. STONE GW, Ellis SG, Gori T, Metzger DC, et al
    Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
    Lancet. 2018;392:1530-1540.
    PubMed     Text format     Abstract available
    
    
    
54. WILLEIT P, Ridker PM, Nestel PJ, Simes J, et al
    Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
    Lancet. 2018 Oct 4. pii: S0140-6736(18)31652.
    PubMed     Text format     Abstract available
    
    
    
55. MAFHAM M, Preiss D
    HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32348.
    PubMed     Text format    
    
    
    
56. HERNANDEZ AF, Green JB, Janmohamed S, D'Agostino RB Sr, et al
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32261.
    PubMed     Text format     Abstract available
    
    
    September 2018
57. CAMENZIND E, Popovic B
    Are all drug-eluting stents created equal?
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32334.
    PubMed     Text format    
    
    
    
58. VON BIRGELEN C, Zocca P, Buiten RA, Jessurun GAJ, et al
    Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, ran
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32001.
    PubMed     Text format     Abstract available
    
    
    
59. DEHGHAN M, Mente A, Rangarajan S, Sheridan P, et al
    Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study.
    Lancet. 2018 Sep 11. pii: S0140-6736(18)31812.
    PubMed     Text format     Abstract available
    
    
    
60. HO HH, Ong PJL
    BASKET-SMALL 2: advancing DCB beyond in-stent restenosis.
    Lancet. 2018;392:802-804.
    PubMed     Text format    
    
    
    
61. LANSKY A, Wijns W, Xu B, Kelbaek H, et al
    Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial.
    Lancet. 2018 Sep 3. pii: S0140-6736(18)31649.
    PubMed     Text format     Abstract available
    
    
    
62. PILGRIM T, Piccolo R, Heg D, Roffi M, et al
    Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
    Lancet. 2018;392:737-746.
    PubMed     Text format     Abstract available
    
    
    August 2018
63. VRANCKX P, Valgimigli M, Juni P, Hamm C, et al
    Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, ope
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31858.
    PubMed     Text format     Abstract available
    
    
    
64. CAPODANNO D, Angiolillo DJ
    Aspirin for primary prevention of cardiovascular disease.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31990.
    PubMed     Text format    
    
    
    
65. GAZIANO JM, Brotons C, Coppolecchia R, Cricelli C, et al
    Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31924.
    PubMed     Text format     Abstract available
    
    
    
66. VALGIMIGLI M, Frigoli E, Leonardi S, Vranckx P, et al
    Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31714.
    PubMed     Text format     Abstract available
    
    
    
67. ANGIOLILLO DJ
    Vascular access and antithrombotic therapy in patients with acute coronary syndrome.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31921.
    PubMed     Text format    
    
    
    
68. BLANKENBERG S, Neumann JT, Westermann D
    Diagnosing myocardial infarction: a highly sensitive issue.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31996.
    PubMed     Text format    
    
    
    
69. JEGER RV, Farah A, Ohlow MA, Mangner N, et al
    Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31719.
    PubMed     Text format     Abstract available
    
    
    
70. SHAH ASV, Anand A, Strachan FE, Ferry AV, et al
    High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31923.
    PubMed     Text format     Abstract available
    
    
    
71. OIKONOMOU EK, Marwan M, Desai MY, Mancio J, et al
    Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31114.
    PubMed     Text format     Abstract available
    
    
    
72. MAHABADI AA, Rassaf T
    Imaging of coronary inflammation for cardiovascular risk prediction.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31716.
    PubMed     Text format    
    
    
    
73. MENTE A, O'Donnell M, Rangarajan S, McQueen M, et al
    Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study.
    Lancet. 2018;392:496-506.
    PubMed     Text format     Abstract available
    
    
    
74. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    PubMed     Text format     Abstract available
    
    
    July 2018
75. THEKEN KN, Grosser T
    Weight-adjusted aspirin for cardiovascular prevention.
    Lancet. 2018 Jul 12. pii: S0140-6736(18)31307.
    PubMed     Text format    
    
    
    
76. DOWLING C, Firoozi S, Brecker S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:28.
    PubMed     Text format    
    
    
    
77. FRANCIS DP, Al-Lamee R
    Percutaneous coronary intervention for stable angina in ORBITA - Authors' reply.
    Lancet. 2018;392:28-30.
    PubMed     Text format    
    
    
    
78. BANNING A, Redwood S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:28.
    PubMed     Text format    
    
    
    
79. BAUER A, Rizas KD, Massberg S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:27.
    PubMed     Text format    
    
    
    
80. REED GW, Kapadia SR
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:27-28.
    PubMed     Text format    
    
    
    
81. POCOCK SJ
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:26-27.
    PubMed     Text format    
    
    
    
82. BARAKAT MF, Simitsis P
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:26.
    PubMed     Text format    
    
    
    
83. TU T, Liu Q, Hu X, Zhou S, et al
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25.
    PubMed     Text format    
    
    
    
84. MUTHALALY RG, Nerlekar N, Brown AJ
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25-26.
    PubMed     Text format    
    
    
    
85. DEGRELL P, Picard F, Varenne O
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25.
    PubMed     Text format    
    
    
    June 2018
86. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
    Endpoints in diabetes cardiovascular outcome trials.
    Lancet. 2018;391:2412.
    PubMed     Text format    
    
    
    
87. MARIATHAS M, Curzen N
    Troponin assays: developing indications.
    Lancet. 2018;391:2398-2399.
    PubMed     Text format    
    
    
    
88. DEVEREAUX PJ, Duceppe E, Guyatt G, Tandon V, et al
    Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
    Lancet. 2018;391:2325-2334.
    PubMed     Text format     Abstract available
    
    
    
89. IKEMURA N, Sawano M, Ueda I, Fukuda K, et al
    Consequence of reimbursement policy alteration for urgent PCI in Japan.
    Lancet. 2018;391:2208-2209.
    PubMed     Text format    
    
    
    May 2018
90. MONTAIGNE D, Coisne A, Marechal X, Lefebvre P, et al
    Daytime variations in perioperative myocardial injury - Authors' reply.
    Lancet. 2018;391:2106.
    PubMed     Text format    
    
    
    
91. SPADACCIO C, Dalby M, Danton MHD
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2105-2106.
    PubMed     Text format    
    
    
    
92. LUCCHINETTI E, Zaugg M
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2104-2105.
    PubMed     Text format    
    
    
    
93. BARTMAN CM, Oyama Y, Eckle T
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2104.
    PubMed     Text format    
    
    
    
94. BRILAKIS ES, Edson R, Bhatt DL, Goldman S, et al
    Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.
    Lancet. 2018 May 11. pii: S0140-6736(18)30801.
    PubMed     Text format     Abstract available
    
    
    
95. PYLYPCHUK R, Wells S, Kerr A, Poppe K, et al
    Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.
    Lancet. 2018 May 4. pii: S0140-6736(18)30664.
    PubMed     Text format     Abstract available
    
    
    
96. DAMEN JAAG, Hooft L, Moons KGM
    Contemporary cardiovascular risk prediction.
    Lancet. 2018 May 4. pii: S0140-6736(18)30842.
    PubMed     Text format    
    
    
    April 2018
97. DEHGHAN M, Mente A, Yusuf S
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple? - Authors' reply.
    Lancet. 2018;391:1681-1682.
    PubMed     Text format    
    
    
    
98. HANSEL B, Roussel R, Giral P
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1680.
    PubMed     Text format    
    
    
    
99. KLEBER ME, Delgado GE, Dawczynski C, Lorkowski S, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1680-1681.
    PubMed     Text format    
    
    
    
100. CAO XP, Tan CC, Yu JT
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1679-1680.
     PubMed     Text format    
     
     
     
101. CARBONE S, Billingsley H, Abbate A
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1679.
     PubMed     Text format    
     
     
     
102. LORKOWSKI S, Richter M, Linseisen J, Watzl B, et al
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1678-1679.
     PubMed     Text format    
     
     
     
103. ROSSOUW JE, Prentice RL
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1677.
     PubMed     Text format    
     
     
     
104. BHOPAL RS, Misra A
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1677-1678.
     PubMed     Text format    
     
     
     
105. MANN J, Meerpohl J, Nishida C, McLean R, et al
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1676.
     PubMed     Text format    
     
     
     
106. REYNOLDS AN
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1676.
     PubMed     Text format    
     
     
     
107. KAHLEOVA H, Crosby L, Levin S, Barnard ND, et al
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1676-1677.
     PubMed     Text format    
     
     
     
108. CHU DK, Kim LH, Young PJ, Zamiri N, et al
     Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis.
     Lancet. 2018;391:1693-1705.
     PubMed     Text format     Abstract available
     
     
     March 2018
109. ALKHALIL M
     Bioresorbable polymer drug-eluting stents.
     Lancet. 2018;391:936.
     PubMed     Text format    
     
     
     
110. KANDZARI DE, Mauri L, Koolen JJ, Doros G, et al
     Bioresorbable polymer drug-eluting stents - Authors' reply.
     Lancet. 2018;391:936-937.
     PubMed     Text format    
     
     
     
111. SHAH R
     Bioresorbable polymer drug-eluting stents.
     Lancet. 2018;391:935-936.
     PubMed     Text format    
     
     
     
112. MOTOVSKA Z, Bhatt DL
     12 months of DAPT after acute coronary syndrome still beats 6 months.
     Lancet. 2018 Mar 9. pii: S0140-6736(18)30612.
     PubMed     Text format    
     
     
     
113. HAHN JY, Song YB, Oh JH, Cho DK, et al
     6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
     Lancet. 2018 Mar 9. pii: S0140-6736(18)30493.
     PubMed     Text format     Abstract available
     
     
     February 2018
114. HEAD SJ, Milojevic M, Daemen J, Ahn JM, et al
     Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
     Lancet. 2018 Feb 22. pii: S0140-6736(18)30423.
     PubMed     Text format     Abstract available
     
     
     
115. BHATT DL
     CABG the clear choice for patients with diabetes and multivessel disease.
     Lancet. 2018 Feb 22. pii: S0140-6736(18)30424.
     PubMed     Text format    
     
     
     
116. PAULES CI, Subbarao K
     Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
     Lancet. 2018;391:427-428.
     PubMed     Text format    
     
     
     
117. CALDEIRA D, Ferreira JJ, Costa J
     Influenza vaccination and prevention of cardiovascular disease mortality.
     Lancet. 2018;391:426-427.
     PubMed     Text format    
     
     
     January 2018
118. JOBS A, Desch S, Thiele H
     Great expectations - Authors' reply.
     Lancet. 2018;391:306-307.
     PubMed     Text format    
     
     
     
119. LEMESLE G, Laine M, Pankert M, Puymirat E, et al
     Great expectations.
     Lancet. 2018;391:306.
     PubMed     Text format    
     
     
     
120. ANAND SS, Bosch J, Eikelboom JW, Connolly SJ, et al
     Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
     Lancet. 2018;391:219-229.
     PubMed     Text format     Abstract available
     
     
     
121. BOCHATON T, Ovize M
     Circadian rhythm and ischaemia-reperfusion injury.
     Lancet. 2018;391:8-9.
     PubMed     Text format    
     
     
     
122. BROWN DL, Redberg RF
     Last nail in the coffin for PCI in stable angina?
     Lancet. 2018;391:3-4.
     PubMed     Text format    
     
     
     
123. GERBER RT, Gershlick AH
     A SENIOR moment? Bare-metal stents in elderly patients.
     Lancet. 2018;391:4-6.
     PubMed     Text format    
     
     
     December 2017
124. SCHUMACHER H, Mahfoud F, Bohm M
     Overestimation of cardiovascular outcome incidence - Authors' reply.
     Lancet. 2017;390:2547.
     PubMed     Text format    
     
     
     
125. YE Y, Fonseca R
     Overestimation of cardiovascular outcome incidence.
     Lancet. 2017;390:2546-2547.
     PubMed     Text format    
     
     
     
126. THURSTON GD, Newman JD
     Walking to a pathway for cardiovascular effects of air pollution.
     Lancet. 2017 Dec 5. pii: S0140-6736(17)33078.
     PubMed     Text format    
     
     
     
127. SINHARAY R, Gong J, Barratt B, Ohman-Strickland P, et al
     Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cr
     Lancet. 2017 Dec 5. pii: S0140-6736(17)32643.
     PubMed     Text format     Abstract available
     
     
     
128. DE WINTER RJ, Katagiri Y, Asano T, Milewski KP, et al
     A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 tri
     Lancet. 2017 Dec 1. pii: S0140-6736(17)33103.
     PubMed     Text format     Abstract available
     
     
     November 2017
129. RIDKER PM, MacFadyen JG, Everett BM, Libby P, et al
     Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
     Lancet. 2017 Nov 13. pii: S0140-6736(17)32814.
     PubMed     Text format     Abstract available
     
     
     
130. CONNOLLY SJ, Eikelboom JW, Bosch J, Dagenais G, et al
     Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
     Lancet. 2017 Nov 10. pii: S0140-6736(17)32458.
     PubMed     Text format     Abstract available
     
     
     
131. PRABHAKARAN D, Anand S, Watkins D, Gaziano T, et al
     Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.
     Lancet. 2017 Nov 3. pii: S0140-6736(17)32471.
     PubMed     Text format     Abstract available
     
     
     
132. AL-LAMEE R, Thompson D, Dehbi HM, Sen S, et al
     Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
     Lancet. 2017 Nov 1. pii: S0140-6736(17)32714.
     PubMed     Text format     Abstract available
     
     
     October 2017
133. VARENNE O, Cook S, Sideris G, Kedev S, et al
     Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.
     Lancet. 2017 Oct 31. pii: S0140-6736(17)32713.
     PubMed     Text format     Abstract available
     
     
     
134. MONTAIGNE D, Marechal X, Modine T, Coisne A, et al
     Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbalpha antagonism: a single-centre propensity-matched cohort study and a randomised study.
     Lancet. 2017 Oct 26. pii: S0140-6736(17)32132.
     PubMed     Text format     Abstract available
     
     
     
135. BYRNE RA, Schuster T
     Biodegradable polymer drug-eluting stents: caveat emptor.
     Lancet. 2017;390:1814-1816.
     PubMed     Text format    
     
     
     September 2017
136. LEAR SA, Hu W, Rangarajan S, Gasevic D, et al
     The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study.
     Lancet. 2017 Sep 21. pii: S0140-6736(17)31634.
     PubMed     Text format     Abstract available
     
     
     August 2017
137. SIBBING D, Aradi D, Jacobshagen C, Gross L, et al
     Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
     Lancet. 2017 Aug 25. pii: S0140-6736(17)32155.
     PubMed     Text format     Abstract available
     
     
     
138. RIDKER PM, MacFadyen JG, Thuren T, Everett BM, et al
     Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
     Lancet. 2017 Aug 25. pii: S0140-6736(17)32247.
     PubMed     Text format     Abstract available
     
     
     
139. JINATONGTHAI P, Kongwatcharapong J, Foo CY, Phrommintikul A, et al
     Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.
     Lancet. 2017;390:747-759.
     PubMed     Text format     Abstract available
     
     
     April 2017
140. SHAH R
     Optical coherence tomography-guided PCI.
     Lancet. 2017;389:1607.
     PubMed     Text format    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: